SWISS-MEDICAL-GROUP
24.9.2020 17:56:11 CEST | Business Wire | Press release
Swiss Medical Group (SMG) Holding Luxembourg S.A., leading the development of STARKS Age-Management in Europe and Asia, announced today the acquisition of CoreMedica Europe, to expand in Europe and the rest of the world.
CoreMedica Europe recently made the headlines in Switzerland for combining a COVID-19 Screening Test and Immunity profile with its existing home self-collection kit that allows customers to collect a few drops of blood and send them by mail to CoreMedica Europe’s accredited laboratory in Geneva to screen the anti-SARS-COV-2 IgG antibody and assess any previous infection to SARS-COV-2, the virus responsible for COVID disease, and analyze a set of 5 key biomarkers known to support the immune system (vitamin D, zinc, magnesium, copper, selenium) so as to receive personalized actionable recommendations to help patients build up their natural defenses against the effects of a next potential viral infection.
“In this epidemic and containment context the essential objective of CoreMedica Europe is to allow a patient to collect a few drops of blood at home without involving healthcare personnel and to carry out this serology test in a controlled laboratory environment. From 3 drops of blood taken from your fingertip, our test can tell if someone has been infected with the coronavirus in the past and can help to clarify their general immune status by assessing key markers in the blood” says Dr Jean-Marc Leroux, CEO of CoreMedica Europe.
“With this test we are putting our expertise in testing and personalized recommendations at the service of the fight against COVID 19, with a set of key biomarkers known to support someone's immune system and a precise summary of the results so as to help them strengthen their natural defenses against the effects of the next potential viral infection” says Pierre-Edouard Sottas, CSO of CoreMedica Europe.
CoreMedica expertise goes beyond COVID-19 serological testing and its competitive advantage lies in the personalized analysis of biological data on three main axes:
- Collection of health data by means of home self-collection kits of a few drops of blood,
- Analysis of large quantities of bio-markers, with a unique know-how developed over several years,
- Personalized recommendations using patented technology applied in the field of immunity, nutrition, sports, and anti-aging.
“The objective of SMG is to integrate CoreMedica Europe's unique expertise in the field of blood tests and personalized recommendations into the network of anti-aging clinics that SMG is developing in Europe, so as to improve P4 models in the field of anti-aging and foster preventative care, thereby reducing the costs of treatments” , says Francois Marland, Chairman and CEO of Swiss Medical Group and Chairman of CoreMedica Europe.
SMG has already tested the market with age-management clinics in France, Italy and Greece, the on-going development of eight more clinics in Germany in 2020-2021, and a roll-out plan of 52 age-management clinics in Europe by 2025, developed either by organic growth or by the acquisition of well-known practices.
As part of the deal, SMG took over the operations of CoreMedica Europe in Geneva, the team and its expertise, the authorizations, and all associated patents, algorithms and other intellectual property, as well as negotiated an exclusive distribution agreement in North America with CoreMedica Laboratories Inc., a CAP accredited and CLIA certified laboratory based in the United States.
About Swiss Medical Group:
As a backdrop, Swiss Medical Group Holding invests in the development of companies and clinics in the health sector, including STARKS Age Management, whose activity is to offer a one-stop-shop solution in terms of internal and external age management, including hair, aesthetics, orthopedics, blood tests, digital analysis and health maintenance recommendations, as well as the distribution of well-being or anti-aging products, protocols and therapies.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a patient’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018, CoreMedica expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005730/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IHS Towers Publishes 2025 Sustainability Report26.5.2026 12:34:00 CEST | Press release
IHS Holding Limited (NYSE: IHS) (“IHS Towers”) group, one of the largest independent owners, operators, and developers of shared communications infrastructure in the world by tower count, has today published its 2025 Sustainability Report. The report covers sustainability activities from January 1, 2025 to December 31, 2025 and demonstrates IHS Towers’ continued commitment to its stakeholders, including, but not limited to, its employees, customers, suppliers, local communities, regulators, governments and shareholders. IHS Towers’ vision is to help create a connected world, where mobile connectivity promotes continued economic growth and social development. The communications infrastructure it provides is vital to enabling that connectivity. In 2025, IHS Towers continued to advance its four-pillar sustainability strategy – focusing on ethics and governance, environment and climate change, education and economic growth, our people and communities – as detailed in this report. Sam Darwi
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 202626.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies Global Healthcare Conference on June 3, 2026 and will participate in a fireside chat at 12:45pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational CO
BeOne Medicines to Present at the Goldman Sachs 47th Annual Global Healthcare Conference26.5.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com
GlobalPlatform Launches Pavona: The First Open Silicon Distribution with Production-Grade Post-Quantum Cryptography26.5.2026 12:00:00 CEST | Press release
Founding members — including Agile Analog, Analog Devices, Baochip, CrossBar, Max Planck Institute for Security and Privacy, Meta, University of Oxford, SIMPLE Crypto Association, Qualcomm Technologies, Tenstorrent, Winbond, and ZeroRISC — join community-led initiative to deliver certification-ready, composable silicon IP from datacenter to IoT. GlobalPlatform today launched Pavona, an open-source silicon distribution that delivers production-quality, certification-ready IP components and reference top-level designs — including the first openly available post-quantum cryptography (PQC) stack for embedded silicon. The distribution includes two successfully taped-out reference designs—a standalone chip root of trust and an integrated root of trust for chiplet architectures fabricated at TSMC 3nm (N3). Pavona provides a composable framework for building secure-by-default silicon aligned with FIPS 140-3 and Common Criteria certification requirements. Twelve founding members have already co
Croma Skincare – Where Science Meets Skin26.5.2026 11:43:00 CEST | Press release
With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines. Building on 50 years of experience in hyaluronic acid, Croma Pharma developed this skincare range to bridge the gap between in-clinic treatments and at-home care. The result is a streamlined portfolio that supports key skin needs such as hydration, glow, balance, and protection. The formulations combine high-performance actives including niacinamide, peptides, hyaluronic acid, and plant stem cells with lightweight, fast-absorbing textures that strengthen the skin barrier and enhance overall skin health. Hero products include: THE GLOW - a 20% stabilized vitamin C serum for radiance, antioxidant protection,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom